What People Are Saying - 340B Matters
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15622,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive
“In taking this position, HRSA is eliminating certain high cost drugs that are available through the 340B Program. In terms of the administrative burden required to implement this proposed change, the impact would be significant to track and monitor the actual reimbursement of drugs, which can occur up to one year following the provided service.”
Kyle Townsend, Billings Clinic
“This is a program that provides needed medicines for our nation’s desperately poor.”
Senator Collins (R - ME)
“This new mega-guidance rule could handicap our facility from providing needed care for our rural patients. Please reconsider this restriction.”
Joseph Jeffries, Barnesville Hospital
“In areas throughout New Jersey, this proposed change could result in higher patient costs, reduced patient access and reduced availability of infusion services in a given area, potentially including the elimination of these services altogether.”
Anonymous, New Jersey Hospital Association
“We currently use 340B medications for treating specialty disease states like Hepatitis C, heart disease, cancer, etc. through referrals to specialty providers. The financial impact of not being able to provide medications through the 340B program will affect our ability to provide other services to the CHC program. For example, we currently provide a collaborative for diabetes clinics that includes a pharmacist in our treatment team. We cannot bill for the pharmacist services so we will not be able to continue that service if we cannot offset the costs from the savings from the 340B programs. This service has benefited many patients and improved outcomes. We were hoping to expand this service, because of the 340B savings to our other clinic sites, but if the mega-guidance is adopted as is, this expansion will be compromised and patient care will suffer as a result”
Carol Millage, Santa Barbara Public Health Department
“Most of our 3408 patients live within a 15 to 20 minute radius of the hospital but would have to drive 60 to 90 minutes each way if our 3408 program is no longer available to them. This presents an unnecessary hardship”
Jeremy Biggs, Cumberland Medical Center
“We are extremely concerned about the harmful effect this proposal would have on our ability to provide high quality care to the most fragile patients in our region. By strategically leveraging the savings achieved by the 340B program, SVMC’s transitional care program is enabled to shepherd high risk patients across the care continuum and reduces healthcare spending.”
Ray Smith, Southwestern Vermont Medical Center
“Approximately 1,400 patients receive chemotherapy/ambulatory infusion annually. TennCare and Self-Pay patients represent 17% of the volume. Our patient population will be forced to drive over 50 miles for treatment, while they could have been provided access to the same services within a few miles of their homes. LeConte Medical Center is located in an area where the patient population may refuse the additional costs and time of driving long distances resulting in not receiving lifesaving treatments.”
Jenny Hanson, LeConte Medical Center

Want To Stay Up-To-Date On The Latest 340B News?